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a b s t r a c t
Aim of the study: To deﬁne the effectiveness of ganglion Impar block in improving neuro-
pathic pain.
Materials and methods: Patients who had pain around the coccyx formore than threemonths
and did not respond to conservative treatment were included in this study. All the patients
underwent ﬂuoroscopy guided transsacrococcygeal ganglion Impar block with injecting
3 mL of 0.5% bupivacaine, 2 mL saline, and 1 mL (40 mg) of methylprednisolone. Patients
were evaluated with visual analog scale (VAS) for pain, Leeds assessment of neuropathic
symptoms and signs scale (LANSS) for neuropathic pain, Beck depression Inventory (BDI) for
mood and Short-form 12 (SF-12) for quality of life before, 1 month 3 months and 6 months
after the injection. Patients' painless sitting duration was also recorded.
Results: A total of 28 patients were included in the ﬁnal analyses. VAS and LANSS scores
improved signiﬁcantly throughout the follow-up periods. BDI scores also improvedwhile SF-
12 scores did not show signiﬁcant changes. Painless sitting period of the patients' improved
signiﬁcantly.
Conclusions: Ganglion Impar block is effective in decreasing the neuropathic component of
chronic coccygodynia. This improves painless sitting in patients but its reﬂections on quality
of life is not clear.
© 2018 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.* Corresponding author at: Fevzi Cakmak Mah Muhsin Yazicioglu Cad Ustkaynarca Pendik, Istanbul, Turkey.
E-mail address: ozgekenis@gmail.com (O. Kenis-Coskun).
https://doi.org/10.1016/j.pjnns.2018.08.006
0028-3843/© 2018 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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usually worsens by prolonged sitting or changing positions
from sitting to standing up. It is seen more frequently in
women and can be related to trauma or giving birth [1]. The
abnormal mobility of the coccyx is suggested as a risk factor,
while it is seen more frequently in patients with increased
body-mass index [2]. Coccygodynia is a relatively benign
condition and respondswell to conservative treatment such as
the use of pressure relieving cushions and use of medical
treatment like non-steroidal antiiﬂammatory drugs. However,
in some cases, pain persists and requires interventional
approaches [3].
Chronic pain of any etiology can have neuropathic
components due to continuous neuroinﬂammation [4], which
is also accompanied by central sensitization [5]. Chronic
coccygodynia is not very different in mechanism than other
causes of chronic musculoskeletal pain and therefore has
neuropathic components. In both cases, a continuous inﬂam-
matory insult starts as a mechanical injury but turns into a
chronic inﬂammatory state which may alter the responsive-
ness of the neurons involved in the pain pathways [6].
However, the incidence of neuropathic pain accompanying
chronic coccygodynia is unknown.
Ganglion Impar block has been implemented as a relatively
successful method in coccygodynia for the last twenty years.
Ganglion Impar is the sympathetic ganglion located just
anterior to the coccyx and responsible for the pain sensation of
the coccyx and perineal area. Blocking of this ganglion has
been shown to be safe and effective in coccygodynia [7–9].
Since it is a sympathetic ganglion, it would be involved in
neuropathic processes [10], making it a sensible target in the
presence of neuropathic pain.
The aim of this study is to document the effectiveness of
ganglion Impar block in patents with neuropathic pain in the
coccyxs accompanying chronic coccygodynia, that did not
respond to conservative measures such as cushion use and
medication. This study also investigated the effectiveness of
ganglion Impar block in patients' painless sitting time and
pain on palpation on the coccyx. The changed of quality of life
and overall mood has also been documented.Fig. 1 – Patient recruitment flowchart.2. Materials and methods
This study was conducted between April 2017 and September
2017 in Pain Medicine Clinic. Patients with coccygodynia
between the ages of 18–65 who do not respond to conservative
treatment for threemonthshave been recruited anddeﬁned as
patientswith chronic coccygodynia. Exclusion criteriawere: (1)
Any previous injection to the coccygeal region, (2) allergic
reactionhistory to local anesthetics, (3) present infection at the
injection site, (4) presence of bleeding disorders, (5) coccygo-
dynia associated with cancer metastasis or coccygeal fracture,
(6) history of surgery in lumbar or coccygeal region and (7)
having accompanying neurologic disorders that can cause
neuropathic pain such as polyneuropathy. All patients
underwent ganglion Impar block. Patients were not allowedto use any medication and all the previous medications were
discontinued during the follow-up period. Patients were
followed up one month, three months and six months after
the injection. Therefore a single group repeated measures
design was implemented. Patients' painless sitting periods
(min) have also been recorded. In the ﬁnal analyses, only
patients who had neuropathic pain according to their Leeds
assessment of neuropathic symptoms and signs (LANSS)
scores were included. Patient selection and elimination
algorithm have been described in Fig. 1. All patients gave
written informational consent to be part of this study. This
study was approved by the local ethical committee with the
number of 2017/162.
2.1. Ganglion Impar block
One experienced pain medicine specialist has performed the
GIBs under ﬂuoroscopic guidance. With the patient prone, the
intergluteal area was sterilized, and a small amount of local
anesthetic (3 ccs 2% prilocaine, AstraZeneca, Turkey) was
given at achieving blockade of cutaneous and subcutaneous
tissues. The sacrococcygeal joint was visualized via digital
subtraction angiography machine (Inﬁnix-i Core Toshiba
Medical Systems Tochigi, Japan). A 22-gauge spinal needle
was used to reach the ganglion Impar. After a 1 mL injection of
non-ionic contrast and spreading of the dye gives a ''reverse
comma’’ appearance in the lateral view, 3 mL of 0.5%
bupivacaine (AstraZeneca, Turkey), 2 mL saline, and 1 mL
(40 mg) ofmethylprednisolone (Pﬁzer, Turkey)were injected in
the area (Fig. 2).
2.2. Pain evaluation
Patients' overall pain levelswere evaluatedwith a 10 cmvisual
analog scale (VAS). Neuropathic component of the pain was
assessedwith the Leeds assessment of neuropathic symptoms
and signs scale (LANSS). LANSS was developed by Bennett in
2000 to evaluate the neuropathic components of pain. It has
one part of pain questions and a part to evaluate touch and
pinprick sensation. On the LANSS Pain Scale, a score of 12 or
more was classiﬁed as neuropathic pain, and a score under 12
[(Fig._2)TD$FIG]
Fig. 2 – Fluoroscopic view of ganglion Impar block after the
administration of contrast material.
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severity of pain or neuropathic pain itself, just the presence
and absence of it. It is easily administered and validated in
Turkish [11].
2.3. Quality of life and mood evaluation
Quality of life has been evaluated by short form 12 (SF-12). The
SF-12 is a health-related quality-of-life questionnaire consist-
ing of twelve questions that measure eight health domains to
assess physical and mental health [12]. In the ﬁnal analyses,
patients' mood has been evaluated with Beck Depression
Inventory (BDI). BDI is a 21-item, self-report rating inventory
that measures characteristic attitudes and symptoms of
depression. It is an easily applied self-reporting form, and it
is validated in Turkish [13].
2.4. Statistical analyses
A post-hoc sample size analyses was performed after the
ﬁnalization of the study. G-power software package for power
analysis was used (ver. 3.1.6; Franz Faul, Kiel University, Kiel,
Germany).The change in LANSS was used as the primary
outcome measurement. Consequently, as 28 patients were
included in the ﬁnal analyses, the power of the study was
calculated as 0.99 with an effect size of 8.6 and an a level of
0.05. All statistical analyses were performed using Statistical
Package for the Social Sciences version 20.0 (IBM Corp.).
Descriptive statistics were calculated and consisted of the
mean, standard deviation (SD), 95% conﬁdence interval (CI),
and range. Tests of normality were done using Shapiro-Wilks
normality test. According to the normality of the variable, one-
way repeated measures ANOVA or Freidman tests were usedfor continuous variables. The signiﬁcance of pairwise compar-
isons was calculated after Bonferroni corrections were made.
Themean values were reported to give a better understanding
of the data in Freidman analyses. When analyzing the
presence of neuropathic pain after the injections, patients'
LANSS scores were calculated and patients' neuropathic pain
were determined absent or present. The signiﬁcance of these
changes were calculated with McNemar test since it is a
within-subjects design with a dichotomous value. The level of
signiﬁcance was set at p < 0.05.3. Results28 patients were included in the ﬁnal analyses. 23 of the
patients were female (82.1%) with a mean age of 43.75  11.74
(min: 20 max: 65). Mean BMI of the patients was 29.49  4.27
(min: 20.2 max: 37.3). Mean symptom time was 25.9  27.7
months (min:3max:108). 19 patients had a history of trauma to
the coccyx (67.9%).
When the patients VAS levels were analyzed, mean VAS
before injection was 7.89  0.2 [Conﬁdence interval (CI) 7.38–
8.40], while mean VAS after one month 2.39  0.4 (CI 1.53–
3.26), at three months 3.11  0.5 (CI 1.95–4.26) and at six
months 3.89  0.6 (CI 2.56–5.22) (p values for all points are
<0.0001). A similar change was seen in LANSS scores as well
with mean LANSS scores before the injection were 15.1  0.7
(CI 14.4–17.9), after one month 6.46  1.15 (CI 4.09–8.84) after
three months 5.82  1.0 (CI 3.08–7.76) and after six months
6.82  1.0 (CI 4.64–9.01) (p values for all follow up points are
<0.0001) (Fig. 3). When calculated according to its guide, there
were only 7 (25%) patients who had ongoing neuropathic pain
after 1 month, 4 (14%) after 3 months and 5 (17%) after 6
months of the injection. McNemar tests determined these
changes were also statistically signiﬁcant (p < 0.0001 for each
follow-up point).
When the patients' SF-12 scores were analyzed, there were
signiﬁcant improvements in SF-12 physical health domain in 1
month and 3 months after the follow-up, but this improve-
ment seems to disappear after six months. SF-12 mental
health domain showed a signiﬁcant difference only on the 3rd
month (Table 1). BDI scores improved signiﬁcantly after the
injection and this change continued throughout the follow-up
period ( [50_TD$DIFF] able 2). Patients' painless sitting period has also
increased signiﬁcantly after injection as it was 15.07  2.99
min before the injection (CI 8.9–21.25), 82.38  12.64 min after
one month (56.34–108.48), 98.15  12.30 (72.73–123.58) after
three months and 82.11  14.37 min (51.49–111.73) after six
months (p < 0.0001 for all follow up points) (Fig. 4).
We have not seen any major adverse effect in these
patients. Minor adverse effects involving vasovagal reaction
and transient increase in painwere observed in only two of our
patients.
4. DiscussionThis study shows that ganglion Impar block can be effective in
improving the neuropathic pain in coccygodynia. This
Table 1 – Changes in subscales of Short form-12 (SF-12) during follow-up. SD: standard deviation.
Mean  SD (95% CI) Signiﬁcance
SF-12 physical Before injection 33.92  1.65 (30.52–37.32)
SF-12 physical 1 month 41.14  2.05 (36.93–45.35) p = 0.26
SF-12 physical 3 months 42.38  1.81 (38.65–46.11) p = 0.07*
SF-12 physical 6 months 37.91  1.59 (34.63–41.18) p = 0.55
Sf-12 mental before injection 28.89  6.59 (26.34–31.45)
SF-12 mental 1 month 34.50  9.09 (30.98–38.03) p = 0.62
SF-12 mental 3 months 35.75  10.23 (32.78–39.72) p = 0.16
SF-12 mental 6 months 34.61  9.18 (31.05–38.18) p = 0.69
[49_TD$DIFF]* shows statistical signiﬁcance.
Table 2 – Changes in Beck Depression Inventory (BDI)
scores throughout the follow-up. SD: standard deviation.
BDI Mean  SD (95% CI) Signiﬁcance
Before injection 23.37  2.49 (18.24–28.50)
1 month 14.48  1.93 (10.50–18.45) p = 0.001
3 months 13.96  2.33 (9.17–18.75) p = 0.043
6 months 13.03  2.01 (8.89–17.18) p = 0.003
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Fig. 3 – [48_TD$DIFF]Changes of VAS and LANSS scores during follow-up period.
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painless sitting period and improved quality of life.
The concept of neuropathic pain has changed signiﬁcantly
over the last decade. It was described as 'pain initiated or
caused by a primary lesion or dysfunction in the nervous
system' by the International Association for the Study of Pain
(IASP) in 1994. This description has been changed to 'pain
arising as a direct consequence of a lesion or disease affecting
the somatosensory system' in 2008 by a task force initiated by
the IASP Special Interest Group onNeuropathic Pain (NeuPSIG)
in order to describe neuropathic pain more deﬁnitively [14]. It
has also been reported by NeuPSIG that nociceptive pain
conditionsmay cause secondary lesions in the somatosensory
nervous system could ultimately be considered as being partly
neuropathic pain, especially over a long period [15]. Changes inthe central nervous system in chronic pain patients such as
central sensitization and decreased inhibitory signals showed
that a neuropathic pathway is involved in chronic pain [16].
This is especially the case in coccygodynia, where chronic
irritation of coccygeal nerve roots due to the biomechanical
alterations in the coccyx is an important mechanism. It has
been theorized that this nerve root irritation causes sympa-
thetic over activity as well; making sympathetic blocks like
ganglion Impar block a suitable choice [17]. Since the ganglion
Impar is the relay point for the coccygeal pain, coccygeal nerve
block alonemaynot achieve the same results, since it is amore
peripheral approach. Also, the effectiveness of coccygeal block
is notwell-deﬁned in coccygodyniawhile ganglion Impar block
has shown to be successful many times in the literature, and
with different modalities like radiofrequency ablation [18–20].
Inhibition of nociceptive transmission via the blocking of
sympathetic nervous system has an analgesic effect and
decreases sensitization. The simultaneous decrease of VAS
and LANSS in this study points out that an improvement in its
neuropathic component accompanies improvement in pain.
This is logical and expected, but not documented before in the
literature. It must also be kept in mind that LANSS cannot
reﬂect the severity of pain, but the presence and absence of
neuropathic pain, andmust be considered alongwithVAS. The
sympathetic component of pain has not been differentiated by
diagnostic approaches in this study, which is a weakness.
[(Fig._4)TD$FIG]
Fig. 4 – Change of painless sitting period during follow-up.
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components of coccygodynia would give us more information
about the mechanisms.
In this study, only four patients among the 33 referred to
the pain clinic did not have neuropathic pain. It must be kept
in mind that any study that is done in a pain clinic would be
biased about the incidence of neuropathic pain. Coccygodynia
is not a very commonproblem,which response relatively good
to conservativemeasures such as pressure relief cushions and
medications and must be treated conservatively when possi-
ble [21]. The patients referred to pain clinics are the small
percentage of patients with coccygodynia that does not
respond to conservative treatment. The incidence of neuro-
pathic pain among these patients cannot be an indication of
the overall incidence of neuropathic pain in coccygodynia. A
study to determine this should be conducted in a primary care
setting to give us realistic results. This is beyond the scope of
this study, and it must be kept in mind that results of this
study cannot indicate the real incidence.
In coccygodynia pain during sitting is usually the main
problem of the patients. In this study, we have documented
the painless sitting period of the patients during the follow up
to evaluate the effect of the injection on patients' daily lives.
This study showed that there is a signiﬁcant improvement in
this variable and this improvement kept on during the six
months followup period. However, this increase did not reﬂect
the scores on SF-12. Existing quality of life measurements are
not explicitlymade for coccygodynia. Previous studies focused
on pain [8,9] and disability [7], rather than the quality of life,
probably because of this deﬁcit. Developing a proper quality of
life measurement is crucial in coccygodynia to assess the
success of interventions, and this area is currently lacking.
One important limitation of this study is the limited
number of patients involved. Even with a small sample,
ganglion Impar block seems effective. However, to reach solid
conclusions, larger studies implementing different injection
techniques should be planned in the future. Another limita-
tion is the relatively short follow-up period. Previous studies
that span a longer time period showed that repetitiveinterventions for a sustained pain relief might be necessary
in patients with chronic coccygodynia [8]. In this study, all the
patients have received just a single injection, and it would be
impossible to comment on long-termeffects of ganglion Impar
block on neuropathic pain with the results of this study.
5. ConclusionGanglion Impar block is effective in improving the neuropathic
component of coccygodynia along with overall pain sensation
and painless sitting period. The exact effects of these
improvements on patients' quality of life remain unclear.
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